EUVIMEDEUVIMED entdecken
Crossref

Trabekulektomie mit Ologen®-Implantat und Bevacizumab

K Glandorf, C Lommatzsch, C Heinz, J M Koch

Der Ophthalmologe · 2020-05 · 117 (5) · 445-451

DOI: 10.1007/s00347-019-00972-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Der Ophthalmologe, online erschienen am 20.09.2019. Verfasst von K Glandorf und 3 weiteren Autor:innen. Beteiligte Einrichtung: Augenzentrum am St. Franziskus Hospital Münster, Hohenzollernring 74, 48145, Münster, Deutschland. karen.glandorf@augen-franziskus.de. Hauptthemen laut MEDLINE: Trabeculectomy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Trabeculectomy is the most frequent form of glaucoma surgery. Despite the intraoperative use of antimetabolites, such as mitomycin C (MMC) postoperative scarring reactions can cause surgical failure. The subconjunctival placement of an Ologen® implant can avoid wound scarring. The additional application of bevacizumab should reduce angiogenesis and thereby scarring reactions and improve the surgical success rate. METHODS: This was a retrospective single center study of patients with glaucoma after trabeculectomy with MMC. The operation was carried out either without an Ologen® implant (group 1), or with an Ologen® implant as an bevacizumab depot (group 2) or with an Ologen® implant and intrachamber injection of bevacizumab (group 3). The follow-up postoperative observation of intraocular pressure (IOP), complications, subsequent interventions and antiglaucoma treatment was performed for 12 months. RESULTS: There were no significant differences between the groups with respect to IOP, complications, subsequent interventions and postoperative antiglaucoma treatment. The highest success rate (IOP after 12 months ≤15 mm Hg without treatment) was in group 1 (77.5%), followed by group 2 with 63.6% and group 3 with 57.1% (p = 0.34, χ2-test). CONCLUSION: The highest success rate was achieved in group 1 with MMC but without an Ologen® implant or bevacizumab. In this study the additional use of Ologen® implants and bevacizumab in trabeculectomy was found to be a safe operation method but did not provide any additional benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrabeculectomyBevacizumabCollagenGlycosaminoglycansHumansIntraocular PressureMitomycinRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Anti-VEGFCollagen matrix implantFiltration surgeryGlaucomaMitomycin C

Substanzen

Glycosaminoglycanscollagen-glycosaminoglycan copolymerBevacizumabMitomycinCollagen

Autor:innen und Institutionen

  • Augenzentrum am St. Franziskus Hospital Münster, Hohenzollernring 74, 48145, Münster, Deutschland. karen.glandorf@augen-franziskus.de.
  • Augenzentrum am St. Franziskus Hospital Münster, Hohenzollernring 74, 48145, Münster, Deutschland.
  • Zentrum für Augenheilkunde, Universität Duisburg Essen, Essen, Deutschland.

Zitieren

APA

Glandorf, K., Lommatzsch, C., Heinz, C., & Koch, J. M. (2020). Trabekulektomie mit Ologen®-Implantat und Bevacizumab. Der Ophthalmologe, 117(5), 445-451. https://doi.org/10.1007/s00347-019-00972-y

Vancouver

Glandorf K, Lommatzsch C, Heinz C, Koch JM. Trabekulektomie mit Ologen®-Implantat und Bevacizumab. Der Ophthalmologe. 2020;117(5):445-451. doi:10.1007/s00347-019-00972-y

BibTeX
@article{Glandorf2020,
  author = {Glandorf, K and Lommatzsch, C and Heinz, C and Koch, J M},
  title = {Trabekulektomie mit Ologen®-Implantat und Bevacizumab},
  journal = {Der Ophthalmologe},
  year = {2020},
  volume = {117},
  number = {5},
  pages = {445--451},
  doi = {10.1007/s00347-019-00972-y}
}
Kostenlos starten →